The study underscores the pivotal role of pharmacovigilance in safeguarding the health of the public by ensuring the safety of medicines. Initiated in 2010 by the Indian Pharmacopoeia Commission (IPC) with backing from the Ministry of Health and Family Welfare, the Pharmacovigilance Programme of India (PvPI) is dedicated to monitoring adverse drug reactions (ADRs) and ensuring the safety of medicines available in the Indian market.
A significant achievement of the PvPI has been the establishment of 250 Adverse Drug Reaction Monitoring Centres (AMCs) spread across the country. These centers have been instrumental in training healthcare professionals in ADR reporting. Additionally, the PvPI has developed a mobile application to facilitate ADR reporting and has fostered collaborations with international entities like WHO and UMC for data sharing and training.
However, the program faces challenges, notably the under-reporting of ADRs and limited public awareness about the significance of ADR reporting. To address these challenges, there's a pressing need for continuous training, capacity building, and public awareness campaigns. Looking ahead, the PvPI aims to expand its reach, enhance collaborations, and employ advanced data analytics for more effective ADR analysis. The report concludes by emphasizing the continuous efforts required to fortify the PvPI and ensure the safety of medicines for India's populace.
You can submit a specific query to QUAMED experts by clicking on the button below. We will send relevant answers directly to your mailbox.
Submit Query
The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.
ISO 9001:2015 - FS766975
© 2024 - QUAMED
Content of this site is licensed under a Creative Commons License- BY Attribution